Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

XW003

Phase 3Small molecule

HHangzhou Sciwind Biosciences Co., Ltd.

XW003 is one of 48 small molecule programs targeting Obesity. It is currently in Phase 3.

2

Indications

6

Total Trials

4

Active Trials

47

Competitors

Pipeline

Status by Indication[3][1]

Indication

ObesityRecruiting

OSA - Obstructive Sleep ApneaRecruiting

ObesityPhase 2

Recruiting

OSA - Obstructive Sleep ApneaPhase 3

Recruiting

Competition

Competitive Landscape

176 competitors in Obesity

#DrugCompanyPhaseTrials

Maridebart Cafraglutide

Enavogliflozin

Daewoong Pharmaceutical Co. LTD.

Cagrisema

Eloralintide

Naltrexone-Bupropion Combination

CCurrax Pharmaceuticals

Belantamab Mafodotin-Blmf

Efsubaglutide Alfa

SShanghai Yinnuo Pharmaceutical Technology Co., Ltd.

XW003

HHangzhou Sciwind Biosciences Co., Ltd.

Semaglutide or Tirzepatide

NNational and Kapodistrian University of Athens

Actemra

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Obesity

NCT07143227

Q3 2027

Phase 2Recruiting

Obesity

NCT07073417

Q4 2027

Phase 3Recruiting

OSA - Obstructive Sleep Apnea

NCT07387094

Q2 2028

Phase 3Recruiting

OSA - Obstructive Sleep Apnea

NCT07434050

Clinical

Trials by Indication[1]

Obesity3 trials

Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity

Completed·SSciwind Biosciences APAC CO Pty. Ltd.·Phase 2·NCT05111912·206 enrolled

A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)

Recruiting·HHangzhou Sciwind Biosciences Co., Ltd.·Phase 2·NCT07073417·160 enrolled

A Study of XW003 Injection in Chinese Adolescents With Obesity

Recruiting·HHangzhou Sciwind Biosciences Co., Ltd.·Phase 1·NCT07143227·48 enrolled

OSA - Obstructive Sleep Apnea2 trials

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Assess the Efficacy and Safety of XW003 Injections in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy

Recruiting·HHangzhou Sciwind Biosciences Co., Ltd.·Phase 3·NCT07434050·140 enrolled

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Assess the Efficacy and Safety of XW003 Injections in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy

Recruiting·HHangzhou Sciwind Biosciences Co., Ltd.·Phase 3·NCT07387094·140 enrolled

Interaction1 trial

A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin

Completed·HHangzhou Sciwind Biosciences Co., Ltd.·Phase 1·NCT06335134·57 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for XW003. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — XW003 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for XW003. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hangzhou Sciwind Biosciences Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: HHangzhou Sciwind Biosciences Co., Ltd.

Related News